Navigation Links
Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone
Date:1/10/2011

OSAKA, Japan and DURHAM, N.C., Jan. 10, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease. Pioglitazone is the active ingredient currently marketed in Takeda's ACTOS® (pioglitazone HCl).

The TOMM40 biomarker, recently discovered by a team led by Allen Roses, M.D., Chief Executive Officer of Zinfandel, is being developed to identify individuals at high risk of developing Alzheimer's disease within the subsequent five years. Under this license agreement, Takeda and Zinfandel will attempt to prospectively validate the TOMM40 biomarker as a test of individual risk.

"There is intense interest within the medical community in identifying treatments to help delay progression or potentially prevent the onset of Alzheimer's disease, in an effort to reduce the burden of this disease," said Shigenori Ohkawa, Ph.D., Chief Scientific Officer, Takeda Pharmaceutical Company Limited. "We are energized by this partnership and the opportunity to develop an effective treatment for healthy at-risk older adults."

Under the terms of agreement, Zinfandel will receive an upfront payment of $9 million and subsequent payments of up to $78 million for development milestones from Takeda. Additional commercial milestones and royalties were also outlined in the agreement. Takeda will obtain an exclusive license, with the right to sublicense, develop, make, use and commercialize the TOMM40 biomarker assay, and to use the assay to identify high-risk older adults who would be candidates for clinical trials with pioglitazone to evaluate its utility.

"At Zinfandel, we have been exploring pharmacogene
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; Zinfandel Pharmaceutcals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
2. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... today announced that it has received approval from ... of 5,126,044 outstanding common share purchase warrants ("the ... connection with the Company,s May 2013 private placement ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery ... a Memorandum of Understanding with the Feinstein Institute ... New York to collaborate with the ... The collaboration brings together the drug ... clinical expertise of the Feinstein Institute in neurosciences ...
(Date:4/17/2015)... LC Sciences LLC, a leading developer ... it is seeking beta testers for the VariantProâ„¢ ... targeted sequencing technology. The system offers cost-effective, minimal ... detection of rare variants. It utilizes novel and ... will collaborate with beta testers to generate test ...
(Date:4/16/2015)... 17, 2015 Spirax Sarco, the ... released their newly designed, state-of-the-art website in the ... website effectively promotes the Spirax Sarco brand, company ... information that a site visitor might be looking ... capabilities, industries serviced, the latest company news, careers, ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Spirax Sarco website has a new look 2
... Mass., Aug. 17 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... approvable letter from the U.S. Food and Drug ... valrubicin for intravesical,instillation, is the only product approved ... carcinoma in situ (CIS) of the,urinary bladder. ...
... announced today they,have entered into a five-year agreement ... Region 3 to provide RealTime1(TM) (RT1(TM)),software at 15 ... the,US Virgin Islands. The Region 3 Genetics Collaborative, ... for another five-year period.,With this renewal, Region 3 ...
... Inc. (Nasdaq: EMIS ) announced today that it ... common stock and warrants to,purchase 0.4 million shares of ... The five-year warrants will be exercisable at any time ... price of $3.948 per share. The securities in ...
Cached Biology Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... estimate sources and losses of organic carbon in surface waters ... as both sources and sinks for organic carbon. ... streams, which is information that is ultimately needed to improve ... in the atmosphere," said Dr. Richard Smith, a USGS hydrologist ...
... themselves from most bacteria, but some bacteria are able to ... Science on Friday, scientists have identified the genes used ... overwhelm defensive natural products produced by plants of the mustard ... find a way to infect a host and overwhelm the ...
... is a labor-intensive part of commercial peach and nectarine ... been shown to reduce labor requirements and improve fruit ... needed more information about the range of thinning times. ... The Pennsylvania State University and Penn State Cooperative Extension ...
Cached Biology News:What is good for you is bad for infectious bacteria 2String blossom thinner proves effective across stages of bloom development 2
... 100 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
... Sweep- based acquision and ... evoked response type applications. Contains ... many flexible analysis functions including ... measurement plotting. Also includes many ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: